See how Dexcom products can help optimise your patients' glucose control and support their quality of life.
Smart devices sold separately†
A leader in diabetes care
Dexcom is dedicated to developing innovative glucose monitoring technology and products to help patients and Healthcare Professionals improve diabetes management.
As the world's first real-time, integrated CGM (rt-iCGM), the Dexcom G6 Continuous Glucose Monitoring (CGM) System offers a range of features and benefits that help make that possible.
1st mobile CGM system
1st CGM system indicated for non-adjunctive use (insulin dosing without fingersticks*)
1st real-time integrated CGM (rt-iCGM) approved for use in Ireland†
Redefining the CGM landscape
Dexcom delivered the next generation of CGM technology with the development of Dexcom G6: a zero-fingersticks*, accurate1 and interoperable real-time CGM (rt-CGM) system.
Formatted Block Title
Provides exceptional accuracy1
Provides exceptional accuracy1
DEXCOM G6 PERFORMANCE METRICS1
WITH AN OVERALL MARD OF 9% AND A SUSTAINED ACCURACY OVER TIME,1 THE DEXCOM G6 DEMONSTRATES EXCEPTIONAL ACCURACY.
%15/15 (0.8 mmol/L)ǂ
%20/20 (1.1 mmol/L)§
|Overall (Combine study data from paediatrics and adults, see below)||83.3%||93.9%||9.0%|
|Overall accuracy over time|
|Days 4 - 5||85.8%||95.5%||9.4%|
ACCURACY AT VARIOUS RATES OF CHANGE2
RISING OR FALLING, DEXCOM G6 DEMONSTRATES ACCURACY EVEN WHEN LEVELS RAPIDLY OR SLOWLY RISE OR FALL.2
CGM RATE OF CHANGE (mg/(dL · min))
Supports optimal diabetes management
Zero fingersticks*or scanning required
Smart device compatibility¶
Accuracy during critical times3
Supports improved glycaemic outcomes (multiple measures)4-7
Glucose data sharing with loved ones**
Customisable high and low alerts
Learn how continuous glucose monitoring (CGM) is a powerful tool to help improve diabetes management.
Review evidence demonstrating the impact CGM use can have on glycaemic control.
Whether a patient with type 1 using injections, Flash or pump, your patients may benefit.
* If your glucose alerts and readings from Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
† NICE TA151 guidance recommends that CGM is used as an adjunct to multiple daily injections (MDI), with insulin pump therapy generally reserved for patients whose condition is not adequately managed by MDI.
‡ % of CGM readings within ±15 mg/dL of YSI lab reference values ≤ 100mg/dL or ±15% of YSI values > 100mg/dL.
§ Analogous to %15/15 (see previous footnote).
II MARD is a statistical measure of accuracy; the lower the number, the better.
¶Compatible smart devices are sold separately. For a list of compatible smart devices, please visit www.dexcom.com/compatibility.
** Internet connectivity required for data sharing. Following requires the use of the Follow App. Followers should always confirm readings on the Dexcom G6 App or Receiver before making treatment decisions.
1 Shah VN, et al. Diabetes Technol Ther. 2018.
2 Wadwa RP, et al. Diabetes Technol Ther. 2018.
3 Dexcom G6 CGM System User Guide, 2018.
4 Beck RW, et al. JAMA. 2017;317(4):371-378.
5 Reddy M, et al. Diabet Med. 2017.
6 Heinemann L, et al. Lancet. 2018.
7 Welsh JB et al. Diabetes Technol Ther 2019;21(3):128-32.